GNE-6776
Based on 7 publication(s) in Google Scholar
GNE-6776 is a selective and orally bioavailable USP7 inhibitor.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.03%
- CAS. Nr.: 2009273-71-4
- Formel: C20H20N4O2
- Molecular Weight:348.40
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Ubiquitination Compound Library
HY-L050
-
Orally Active Compound Library
HY-L061
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Protease Inhibitor Library
HY-L147
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) GNE-6776
More- Theranostics. 2022 May 16;12(9):4348-4373. [Abstract]
- Theranostics. 2020 Jul 23;10(20):9332-9347. [Abstract]
- Cell Death Discov. 2025 Apr 17;11(1):183. [Abstract]
- Cancer Cell Int. 2025 Feb 21;25(1):60. [Abstract]
- Pharmaceuticals (Basel). 2025 Feb 12;18(2):245. [Abstract]
- J Med Virol. 2025 Jan;97(1):e70168. [Abstract]
- Anim Cells Syst. 2024 May 11;28(1):237-250. [Abstract]
Biologische Aktivität
USP7[1]
GNE-6776 significantly inhibits USP7 at 15 μM. GNE-6776 is a highly selective USP7 inhibitor against both recombinant and endogenous cellular deubiquitinases[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immunodeficient C.B-17 SCID mice (aged 12-16 weeks) with EOL1 AML xenograft[1]
-
Dosage:100 or 200 mg/kg
-
Administration:Oral gavage on a once or twice daily schedule; for 10 days
-
Result:Significant EOL-1 xenograft growth inhibition.
Chemical Information
-
CAS. Nr. 2009273-71-4
-
Appearance Solid
-
Molecular Weight 348.40
-
Formel C20H20N4O2
-
Color White to off-white
-
SMILES
CCC(C(C1=CC=C(O)C=C1)=C(N)N=C2)=C2C3=CC=C(C(NC)=O)N=C3
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Theranostics
RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells. [Abstract]2022 May 16;12(9):4348-4373. PMID: 35673573 -
Theranostics
USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer. [Abstract]2020 Jul 23;10(20):9332-9347. PMID: 32802195 -
Cell Death Discov
USP7 promotes endothelial activation to aggravate sepsis-induced acute lung injury through PDK1/AKT/NF-κB signaling pathway. [Abstract]2025 Apr 17;11(1):183. PMID: 40246841 -
Cancer Cell Int
Targeting the USP7-CDK1 axis suppresses estrogen receptor-positive breast cancer progression. [Abstract]2025 Feb 21;25(1):60. PMID: 39985032 -
Pharmaceuticals (Basel)
Antitumor Activity of USP7 Inhibitor GNE-6776 in Non-Small Cell Lung Cancer Involves Regulation of Epithelial-Mesenchymal Transition, Cell Cycle, Wnt/β-Catenin, and PI3K/AKT/mTOR Pathways. [Abstract]2025 Feb 12;18(2):245. PMID: 40006058 -
J Med Virol
2025 Jan;97(1):e70168. PMID: 39821265 -
Anim Cells Syst
Blocking SLC7A11 attenuates the proliferation of esophageal squamous cell carcinoma cells. [Abstract]2024 May 11;28(1):237-250. PMID: 38741950
Lösungsmittel & Löslichkeit
DMSO : ≥ 100 mg/mL (287.03 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8703 mL | 14.3513 mL | 28.7026 mL | 71.7566 mL |
| 5 mM | 0.5741 mL | 2.8703 mL | 5.7405 mL | 14.3513 mL | |
| 10 mM | 0.2870 mL | 1.4351 mL | 2.8703 mL | 7.1757 mL | |
| 15 mM | 0.1914 mL | 0.9568 mL | 1.9135 mL | 4.7838 mL | |
| 20 mM | 0.1435 mL | 0.7176 mL | 1.4351 mL | 3.5878 mL | |
| 25 mM | 0.1148 mL | 0.5741 mL | 1.1481 mL | 2.8703 mL | |
| 30 mM | 0.0957 mL | 0.4784 mL | 0.9568 mL | 2.3919 mL | |
| 40 mM | 0.0718 mL | 0.3588 mL | 0.7176 mL | 1.7939 mL | |
| 50 mM | 0.0574 mL | 0.2870 mL | 0.5741 mL | 1.4351 mL | |
| 60 mM | 0.0478 mL | 0.2392 mL | 0.4784 mL | 1.1959 mL | |
| 80 mM | 0.0359 mL | 0.1794 mL | 0.3588 mL | 0.8970 mL | |
| 100 mM | 0.0287 mL | 0.1435 mL | 0.2870 mL | 0.7176 mL |
Powered by Bioz